Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes?

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 5, 2014, Pages 533-536

  Bhardwaj, Atul ^a   Kaur, Jatinder ^a   Wuest, Frank ^a   Knaus, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cardiovascular complications; diabetes; endothelial dysfunction; nitric oxide; nitric oxide releasing drugs

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE DONOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC PATIENT; DRUG POTENCY; ENDOTHELIAL DYSFUNCTION; HUMAN; PHARMACODYNAMICS; REVIEW; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; RISK FACTORS;

EID: 84899062435     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.897227     Document Type: Review

References (25)

1. Triggle CR, Ding H. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. J Am Soc Hyper 2010;4(3): 102-15
2. Taddei S, Ghiadoni L, Virdis A, et al. Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm Des 2003;9:2385-402
3. Vanhoutte PM. Endothelium and control of vascular function. State of the Art lecture. Hypertension 1989;13:658-67
4. Virsaladze D, Kipiani V. Endothelial dysfunction in diabetic vasculopathy. Ann Biochem Res Educ 2001;1:44-8
5. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013;34:2444-56
6. Clark CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995;332: 1210-17
7. Murray KM. Calcium-channel blockers for treatment of diabetic nephropathy. Clin Pharm 1991;10:862-5
8. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992;41:912-19
9. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48: 6523-43
10. Calderone V. An update on hybrid drugs in cardiovascular drug research. Expert Opin Drug Discov 2008;3(12):1397-408
11. 2NHOH) cyclooxygenase-2 pharmacophore: synthesis, molecular modeling, and biological evaluation as anti-inflammatory agents. ChemMedChem 2012;7:62-7
12. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000;356: 1255-9
13. Butler AR, Williams DLH. The physiological role of nitric oxide. Chem Soc Rev 1993;22:233-41
14. Toda N, Imamura T, Okamura T. Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus. Pharmacol Ther 2010;127:189-209
15. Floyd JC Jr, Fajans SS, Conn JW, et al. Stimulation of insulin secretion by amino acids. J Clin Invest 1966;45: 1487-502
16. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43: 109-42
17. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298:249-58
18. Félétou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006;291: 985-1002
19. Visentin S, Rolando B, Stilo AD, et al. New 1,4-dihydropyridines endowed with NO-donor and calcium channel agonist properties. J Med Chem 2004;47: 2688-93
20. Kaur J, Bhardwaj A, Huang Z, et al. Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies. J Med Chem 2012;55:7883-91
21. Calderone V, Rapposelli S, Martelli A, et al. O glibenclamide derivatives: prototypes of a new class of nitric oxide releasing anti-diabetic drugs. Bioorg Med Chem 2009;17:5426-32
22. Schmidt HH, Warner TD, Ishii K, et al. Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science 1992;255:721-3
23. Das UN, Krishna MI, Vijay KK, et al. Beneficial effect of l-arginine in non-insulin dependent diabetes mellitus: a potential role for nitric oxide. Med Sci Res 1993;21: 669-70
24. Tsuura Y, Ishida H, Shinomura T, et al. Endogenous nitric oxide inhibits glucose-induced insulin secretion by suppression of phosphofructokinase activity in pancreatic islets. Biochem Biophys Res Commun 1998;252:34-8
25. Jones PM, Persaud SJ, Bjaaland T, et al. Nitric oxide is not involved in the initiation of insulin secretion from rat islets of Langerhans. Diabetologia 1992;35:1020-7